Hepatic and Renal Considerations for Austedo (Deutetrabenazine)
Critical Contraindication
Austedo is absolutely contraindicated in patients with any degree of hepatic impairment 1. This is a black-and-white exclusion criterion—do not initiate this medication if liver disease is present.
Hepatic Considerations
Absolute Contraindication
- Any hepatic impairment is an absolute contraindication to Austedo therapy 1
- This applies to all severity levels (mild, moderate, severe)
- The FDA labeling explicitly states patients with hepatic impairment cannot receive this medication 1
Pre-Treatment Assessment Required
Before initiating Austedo, you must:
- Obtain baseline liver function tests (AST, ALT, alkaline phosphatase, bilirubin)
- Document absence of liver disease
- Screen for risk factors: alcohol use, viral hepatitis, metabolic liver disease, concurrent hepatotoxic medications
Clinical Pitfall
Do not confuse Austedo (deutetrabenazine) with methylphenidate products. The evidence provided includes extensive discussion of methylphenidate hepatotoxicity 2, 3, but these are entirely different drug classes. Austedo is a VMAT2 inhibitor used for chorea and tardive dyskinesia, not ADHD. The hepatic contraindication for Austedo is based on altered pharmacokinetics in liver disease 1, not hepatotoxicity risk.
Renal Considerations
No Specific Renal Contraindications
- The FDA labeling does not list renal impairment as a contraindication 1
- No specific dose adjustments are mentioned for renal dysfunction in the provided drug labeling
- Standard monitoring of renal function is prudent but not specifically mandated
Practical Approach
- Obtain baseline renal function (creatinine, eGFR) as part of standard pre-treatment assessment
- Monitor for drug interactions that may affect renal function
- Be aware that patients with severe renal disease often have concurrent medical complexity requiring closer monitoring
Key Monitoring Strategy
For hepatic function:
- Baseline LFTs are mandatory
- Any elevation or history of liver disease = absolute contraindication
- Do not attempt dose reduction or "cautious use"—the contraindication is categorical
For renal function:
- Baseline assessment recommended as standard practice
- No specific restrictions or dose adjustments required based on available labeling
- Monitor for potential drug-drug interactions affecting renal clearance
Critical Drug Interactions Affecting Organ Function
Beyond organ impairment itself, Austedo has several absolute contraindications 1:
- MAOIs (14-day washout required)
- Reserpine (20-day washout required)
- Tetrabenazine or valbenazine (do not co-administer)
These interactions are independent of hepatic/renal status but compound risk in vulnerable patients.